All In Biotech

Drug Trial Radar · NCT00222573

Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction

Clopidogrel Or Metoprolol in Myocardial Infarction Trial

Last checked: Nov 19, 2026Latest source record: May 5, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 46,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

46,000

Actual

Start

Jul 1999

Primary completion

Not stated

Study completion Feb 2005

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi; AstraZeneca
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible provided they were thought to have ST elevation or other ischaemic ECG abnormality with no clear indication for, or contraindication to, trial treatment. All patients were to be given 162 mg ASA daily and, in addition, 75 mg clopidogrel daily or matching placebo for 4 weeks or until prior discharge or death. (Patients were also randomised separately in a 2 X 2 factorial design between metoprolol versus placebo.) The two main study endpoints are death and the composite outcome of death, non-fatal reinfarction or stroke during the scheduled treatment period in hospital.

Conditions

  • Acute Myocardial Infarction

Interventions

  • clopidogrel and metoprololDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death and the composite outcome of death, non-fatal reinfarction or stroke

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Institute of Cadiovascular diseases, Fuwai hospital, Chinese academy of medical sciences

    Beijing, China

  • Clinical Trial Service Unit and Epidemiological Studies Unit

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.